Coronavirus particles, illustration. Today the governing Board of the California Institute for Regenerative Medicine (CIRM) approved new clinical trials for COVID-19 and sickle cell disease (SCD) and two earlier stage projects to develop therapies for COVID-19. Dr. Michael Mathay, of the University of California at San Francisco, was awarded $750,000 for a clinical trial testing … Continue reading CIRM Board Approves Clinical Trials Targeting COVID-19 and Sickle Cell Disease
Basic Research
Promising results from CIRM-funded projects
Severe Leukocyte Adhesion Deficiency-1 (LAD-1) is a rare condition that causes the immune system to malfunction and reduces its ability to fight off viruses and bacteria. Over time the repeated infections can take a heavy toll on the body and dramatically shorten a person’s life. But now a therapy, developed by Rocket Pharmaceuticals, is showing … Continue reading Promising results from CIRM-funded projects
Helping the blind see – mice that is
When I first saw the headline for this story I thought of the nursery rhyme about the three blind mice. Finally, they’ll be able to see the farmer’s wife coming at them with a carving knife. But the real-world implications are of this are actually pretty exciting. Researchers at the National Institute of Health’s National … Continue reading Helping the blind see – mice that is
Cashing in on COVID-19
Coronavirus particles, illustration. Courtesy KTSDesign/Science Photo Library As the coronavirus pandemic continues to spread, one of the few bright spots is how many researchers are stepping up and trying to find new ways to tackle it, to treat it and hopefully even cure it. Unfortunately, there are also those who are simply trying to cash … Continue reading Cashing in on COVID-19
An advocate’s support for CIRM’s COVID-19 funding
Patient Advocates play an important role in everything we do at the stem cell agency, helping inform all the decisions we make. So it was gratifying to hear from one of our Advocates par excellence, Adrienne Shapiro, about her support for our Board's decision to borrow $4.2 million from our Sickle Cell Cure fund to … Continue reading An advocate’s support for CIRM’s COVID-19 funding
CIRM Board invests $5 million in emergency funding for coronavirus
Coronavirus In response to the crisis caused by the COVID-19 virus in California and around the world the governing Board of the California Institute for Regenerative Medicine (CIRM) today held an emergency meeting to approve $5 million in rapid research funds targeting the virus. “These are clearly extraordinary times and they require an extraordinary response … Continue reading CIRM Board invests $5 million in emergency funding for coronavirus
Ask the Stem Cell Team About Autism
On March 19th we held a special Facebook Live "Ask the Stem Cell Team About Autism" event. We were fortunate enough to have two great experts - Dr. Alysson Muotri from UC San Diego, and CIRM's own Dr. Kelly Shepard. As always there is a lot of ground to cover in under one hour and … Continue reading Ask the Stem Cell Team About Autism
Can stem cells help people who have had a stroke? Ask the experts.
Stroke is the third leading cause of death and disability in the US. Every 45 seconds someone in the US has a stroke. Every year around 275,000 people die from a stroke many more survive but are often impaired by the brain attack. The impact is not just physical, but psychological and emotional. It takes … Continue reading Can stem cells help people who have had a stroke? Ask the experts.
Ask the Stem Cell Team About Autism
Do an online search for “autism stem cells” and you quickly come up with numerous websites offering stem cell therapies for autism. They offer encouraging phrases like “new and effective approach” and “a real, lasting treatment.” They even include dense scientific videos featuring people like Dr. Arnold Caplan, a professor at Case Western Reserve University … Continue reading Ask the Stem Cell Team About Autism
Big time validation for early support
It’s not every day that a company and a concept that you helped support from the very beginning gets snapped up for $4.9 billion. But that’s what is happening with Forty Seven Inc. and their anti-cancer therapies. Gilead, another California company by the way, has announced it is buying Forty Seven Inc. for almost $5 … Continue reading Big time validation for early support
The Stem Cellar 